NDA 011961 · Lifsa Drugs
Marplan
Isocarboxazid · Oral · Monoamine Oxidase Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Nov 8, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1959
Jul 1, 1959
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Isocarboxazid" as an intervention, any sponsor and status, largest first.
Imperial College LondonAcademic, hospital or other
NCT02323217 · 20 participants · Start Jan 2015 · Primary completion Feb 2016
Drug: Idazoxan; Isocarboxazid · For: Healthy Volunteers; Alzheimer Disease; Molecular Imaging
Sites: London, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Marplan (Isocarboxazid)
2024 spending
$349K
Beneficiaries
84
450 claims
Per beneficiary
$4,158
$4.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $233,616 |
| 2021 | $287,843 |
| 2022 | $301,266 |
| 2023 | $349,145 |
| 2024 | $349,242 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Anticholinergic medication for antipsychotic-induced tardive dyskinesia.
Bergman H, Soares-Weiser K · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- MAOIs in the contemporary treatment of depression.
Thase ME, Trivedi MH, Rush AJ · Neuropsychopharmacology 1995 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.
Soares-Weiser K, Rathbone J, Ogawa Y, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological treatments for atypical depression: A systematic review and network meta-analysis of randomized controlled trials.
Fornaro M, Caiazza C, Pistone L, et al. · Eur Neuropsychopharmacol 2025 · Network Meta-Analysis, Systematic Review
- Monoamine oxidase inhibitor-responsive depression.
Giller E, Bialos D, Riddle M, et al. · Psychiatry Res 1982 · Clinical Trial, Randomized Controlled Trial
- Effectiveness of piracetam in cortical myoclonus.
Brown P, Steiger MJ, Thompson PD, et al. · Mov Disord 1993 · Clinical Trial, Randomized Controlled Trial
Sponsor: Lifsa Drugs
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.